Jay Lieberman claimed in 2018 that the FDA would review a treatment soon.
1 report, 1 independent
Updated Sep 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jay Lieberman claimed in 2018 that the FDA would review a treatment soon.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Jay Lieberman
basketball player
Nothing else this week.
- FDA
Related events
- The FDA is reviewing a drug approval application for a condition involving the company GAD.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- NRx Pharmaceuticals and TMS are undergoing various reviews with the FDA, including guidance on real-world evidence and a ketamine ANDA review.
- A bill has been introduced that seeks FDA evaluation for new therapies, specifically endorsing legislation focused on veteran care.
- Fox News reports on agency actions and challenges as the FDA nominee faces confirmation hearing pressure.